My Home About Me

by Mark S. Senak
Eye On FDA



Since my last update to approvable letters, there have been several more. The latest to add to the list is the much anticipated decision regarding Dendreon's (DNDN) Provenge. The company announced the receipt of a "Complete Response Letter" which is the new lingo for "Approvable Letter".

You will remember that Approvable Letters or Complete Response Letters (CRL) are issued when the division overseeing the approval process - the Center for Biologics Evaluation and Research - decides that after reviewing the application for approval, more information is needed. That can mean something as simple as label language, a risk management program, a re-cut of existing data or new data in the form of new clinical trials. You will not find the content of the letter on the FDA Web site.

According to the company press release, "[t]he FDA has requested additional clinical data in support of the efficacy claim contained in the BLA. The Company is seeking a clarification from the FDA as to the nature of the data that is being requested. The FDA has also requested additional information with respect to the chemistry, manufacturing and controls (CMC) section of the BLA, which the Company believes it can supply to the FDA in a timely manner."

This past March, on the efficacy question, the Cellular, Tissue and Gene Therapies Advisory Committee had voted 13-4 in favor of efficacy - but the nature of such a committee is "advisory" and the FDA actions can depart from the recommendations of the committee.

There are many reasons for the anticipation of Provenge and it was on Fast Track consideration. This is an example, however, of the fact that Fast Track does not always indicate a product approval is imminent.

Mitchell H. Gold, MD, president and chief executive officer of Dendreon, said in the release, "We are committed to working closely with the FDA to resolve these questions in a timely and efficient manner to bring PROVENGE to patients with advanced prostate cancer who currently have few appealing treatment options."

I will update the link on Eye on FDA with more approvable letters over this coming weekend. For more on approvable letters, see my prior posting on What Do Approvable Letters Mean?


Source: EyeOnFDA.com



RELATED READING:
- Dendreon Nailed by FDA
- Dendreon Option Premiums Remain Astronomical
- Dendreon, A Biotech Gift That Keeps On Giving!
- Dendreon's New 'Hold' Rating at A.G.Edwards

____________________

Solar energy ETFs   Technical chart patterns   support/resistance levels   ETFs (exchange traded funds)   Deron Wagner   options   puts   oil   Ideal ETF setups   emini's S&P 500   earnings   economic data   college degree   skilled labor jobs   US economy   SPDR Gold Trust (GLD) chart pattern   Inflation Rate   Inflation Rate vs Dow Performance   Amateur Investors   exchange traded funds